Analysts have raised their price target for Embla Medical hf. from $35.65 to $37.40, citing improved revenue growth and higher profit margin forecasts.
What's in the News
- Embla Medical hf. reiterated its earnings guidance for the full year 2025 and maintains expectations of 5-6% organic sales growth (Company Statement).
- The company completed a repurchase of 525,733 shares, or 0.12%, for $2.7 million between July 1 and September 30, 2025. In total, 1,449,010 shares, representing 0.34%, have been repurchased for $7 million under the current buyback program (Company Filings).
Valuation Changes
- Fair Value Estimate increased from $35.65 to $37.40, reflecting a modest rise of 4.9%.
- Discount Rate moved up slightly from 7.10% to 7.10%.
- Revenue Growth Forecast improved from 9.19% to 9.42%.
- Net Profit Margin projection rose from 10.12% to 10.65%.
- Future P/E Ratio decreased significantly from 160.93x to 24.45x.
Have other thoughts on Embla Medical hf?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.